NLS Pharmaceutics (NCEL) Stock Price, News & Analysis

Company Overview

NLS Pharmaceutics AG is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, particularly sleep-related conditions. The company’s research is based on the role of orexin, a neurotransmitter involved in regulating wakefulness, arousal and energy balance.

NLS Pharmaceutics has developed a portfolio of small-molecule orexin receptor agonists, including AAZ-A-154 and AAZ-A-172. These investigational compounds are intended to address disorders associated with excessive daytime sleepiness and impaired wakefulness, including narcolepsy and other neurological conditions. The company’s programs remain subject to clinical development and regulatory review.

The company was established in Switzerland and has operated as an international biotechnology business, with corporate activities centered in Europe and research and development directed toward potential global markets. NLS Pharmaceutics has been led by executives including Chief Executive Officer Alex Zwyer, who has been associated with the company since its early development.

Key Stats

• Today's Range: $2.95 to $3.21
• 50-Day Range: $2.86 to $3.97
• 52-Week Range: $1.83 to $24.60
• Volume: 4,772 shs
• Average Volume: 5,934 shs
• Market Capitalization: $17.05 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.00
• Consensus Rating: Hold

NLS Pharmaceutics Stock Analysis - MarketRank™

NLS Pharmaceutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 371st out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

NLS Pharmaceutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

NLS Pharmaceutics has a consensus price target of $23.00, representing about 679.7% upside from its current price of $2.95.

Amount of Analyst Coverage

NLS Pharmaceutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

NLS Pharmaceutics has a P/B Ratio of 1.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.31% of the float of NLS Pharmaceutics has been sold short.

Short Interest Ratio / Days to Cover

NLS Pharmaceutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NLS Pharmaceutics has recently decreased by 23.67%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NLS Pharmaceutics does not currently pay a dividend.

Dividend Growth

NLS Pharmaceutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.60

News Sentiment

NLS Pharmaceutics has a news sentiment score of 1.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for NLS Pharmaceutics this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NLS Pharmaceutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.40% of the stock of NLS Pharmaceutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

NLS Pharmaceutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 9/18/2026
• Today: 9/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NCEL
• Previous Symbol: NASDAQ:NLSP
• CIK: 1783036
• Web: www.nlspharma.com
• Phone: 41-44-512-2150
• Fax: 41-41-618-8009
• Employees: 6
• Year Founded: N/A

Price Target and Rating

• Average Price Target for NLS Pharmaceutics: $23.00
• High Price Target: $23.00
• Low Price Target: $23.00
• Potential Upside/Downside: +679.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.40
• Quick Ratio: 0.76

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.59 per share
• Price / Book: 1.86

Miscellaneous

• Outstanding Shares: 5,780,000
• Free Float: 4,829,000
• Market Cap: $17.05 million
• Optionable: Not Optionable
• Beta: 0.94